title: What is the place of new SGLT-2 inhibitors in therapy and on the formulary?
authors.forename: Stanton R
authors.initials: SR
authors.lastname: Mehr
authors.forename: Marj P
authors.initials: MP
authors.lastname: Zimmerman
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use; D000068896:Canagliflozin; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005569:Formularies as Topic; D005960:Glucosides / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes / Q000627:therapeutic use
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes; D000068896:Canagliflozin; C529054:dapagliflozin; C570240:empagliflozin